Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
You may also be interested in...
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Coming year could feature first-time approvals in the EU for at least five gene therapies.